re: Ann: iSonea Investor Update Presentation ... My quick take...

re: Ann: iSonea Investor Update Presentation ... My quick take on the Investor update presentation is as follows:

Upon comparison with last year's investor update we NOW have the introduction of UK figures. Reading in between the lines I expect a launch in the U.K, well before any U.S. launch. Based on figures a U.K. launch is very significant for the following reasons:

1. All approvals in place. I don't believe any further approvals required.
2. Asthma Purchase Pool in the U.K. is 1.705 million which is nearly 40% of the size of the U.S. anticipated Purchase Pool.
3. Ed Rosen has vast experience in the U.S. and European markets.
4. I believe Dr. Tim Oldham from his years at Mayne Pharma & Hospira has plenty of experience in the Asian, U.K & European markets.

In relation to FDA approval, I believe that the Australian launch although not as successful as initially anticipated has had the effect of getting relevant feedback from users allowing the company to make enhancements to their product.
Thus I believe that these further enhancements would have been incorporated into any final submission to the FDA.

Watch this space. Exciting times ahead.